buyouts news from FierceBiotech
News
Peplin joins list of developers to drop IPO
You can count Peplin on the growing roster of developers that couldn't make a go of an IPO. The Emeryville, CA-based company cited "unfavorable market conditions" as its reason for dropping the IPO, Read more...
Are Mass. lawmakers 'anti-biopharmaceutical'?
After coming up with a billion-dollar program to encourage the growth of the Read more...
Biotech M&A has yet to reach its peak
In analyzing the PowerShares Dynamic Biotech & Genome ETF, a fund made up of primarily small- and medium-cap biotech stocks, Seeking Alpha notes that Big Pharma's appetite for biotech Read more...
On a spree, Roche lands $175M deal for Piramed
Roche snapped up the UK's Piramed today in a $175 million deal that includes a $15 million milestone payment--the latest in a series of new acquisitions. Roche gets Piramed's programs involving Read more...
Novartis CEO: Deals possible in diagnostics, vaccines
Novartis AG CEO Daniel Vasella (photo) concedes that his company is going through a rough stage, but insists that a Read more...
Big Biotech emerges as a shelter in economic storm
Veteran investors have long taken different views of biotechnology, sometimes in the course of a single day. And share prices regularly go on a Read more...
Genzyme gets public backing for $200M expansion
Genzyme is getting some public backing for a $200 million expansion project in the south of Ireland. The Cambridge, MA-based biotech plans to hire about 170 people as it expands its manufacturing and Read more...
Investors remain leery of the biotech industry
Oh, those fickle biotech investors. In Vivo says that biotech investors haven't proven to be very bullish about the money that Read more...
Credit squeeze begins to have an impact on VC
The Star-Ledger offers a new perspective on the investment scene in biotechnology. Analysts tell the newspaper that the credit crunch has put a squeeze on Read more...
Roche invests $387M in biotech
Like so many other pharmaceutical industry giants, Roche has announced plans to increase its stake in biotech, Read more...
Get more buyouts coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets